PGK2 and neoplasm: Combined with the results of network pharmacology and molecular docking, it is predicted that isoscopoletin could inhibit the activities of glycolysis-related proteins GPD2, GPI, HSP90α and PGK2, and affect the metabolic process and energy utilization of tumor cells, thus inhibiting the proliferation of tumor cells and exerting its anti-cancer effect.